YUCAIPA, Calif., Dec. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is an exhibitor at the American Association of Respiratory Care (AARC) 55th international respiratory congress in San Antonio-Texas this coming weekend. Further, CEO Scott Sand, will discuss the AARC exhibition today, December 3, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
The Oxyview Nasal Cannula is the new generation of oxygen delivery equipment being introduced at this year's annual meeting for the American Association for Respiratory care. Ingen stands to close several institutional contracts representing a handsome market-share of the annual $200M oxygen cannula market. The Oxyview Nasal Cannula uses the new patented "gravity-independent" technology and is secured by several U.S. and Foreign patents.
Since 1947, the American Association for Respiratory Care (AARC) has been committed to enhancing professionalism as a respiratory care practitioner, improving performance on the job, and helping to broaden the scope of knowledge essential to the clinician's success. With more than 47,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.
The company introduced the Oxyview Nasal Cannula at last month's MEDICA convention in Germany, leaving with 6 major distributors interested in the new device. The company is bringing a close to its ISO certification this month in order provide product to these new distributors outside the USA.
"Ingen will update the Pink Sheets annual and quarterly report next week in order to bring current reporting obligations with the OTC Pink Sheets. Further, the SEC has responded to our proposal regarding the completion of our required reporting obligations, and the company can now complete the various 10-Q and 10-KSB filings in the next 60 days. This should build confidence with existing and new shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.moneychannel.tv/scas.php
http://www.medox-oxyview.com/Events.html
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.